Email Updates

Search form

You are here

AVAC's Blog: P-Values

  • In the days since the leaders of the ECHO Study announced their findings, AVAC has produced a number of resources to inform advocacy and action. These resources include a new episode of Px Pulse, a webinar, What do the ECHO Study results mean for African women? and a new document, Understanding the Results of the ECHO Study.

    June 28, 2019
    AVAC
  • Please join women and our allies for a global webinar, Thursday, June 27, 9-10am EDT / 3-4pm SAST / 4-5pm EAT, on shaping the post-ECHO agenda for comprehensive sexuality and reproductive health and rights. This emerging agenda will inform an upcoming WHO meeting on this critical subject.

    June 24, 2019
    AVAC
  • This diverse set of some of the latest resources on PrEPWatch.org will help program implementers from a variety of contexts plan for the rollout and scale-up of PrEP.

    June 18, 2019
    Jeanne Baron
  • At a satellite symposium at the South African AIDS Conference linked to a publication in The Lancet, the ECHO trial of contraceptive use and impact on HIV risk released its results. The topline finding: There was no substantial difference in HIV risk among women using DMPA-IM, the LNG implant or the copper IUD.

    June 13, 2019
    AVAC
  • The results of the ECHO Study (Evidence for Contraceptive Options in HIV Outcomes)—a trial designed look at whether three specific contraceptive methods (DMPA-IM, the Jadelle Implant and the Copper IUD) impact women’s HIV risk—will be announced on Thursday, June 13, 14:00–15:30 (South Africa Time) at the South Africa AIDS Conference in Durban.

    June 7, 2019
    AVAC
  • First, the HIV Prevention Market Manager project will present findings from research on what encourages or discourages the effective use of HIV prevention among adolescent girls and young women. And join us to discuss "vaccine hesitancy" and its implications across global health.

    May 20, 2019
    HIV Vaccine, General
    AVAC
  • This HIV Vaccine Awareness Day, Mitchell Warren talks about this promising and perilous time for vaccines. AVAC has an updated toolkit of resources for translating HIV vaccine research with a renewed sense of urgency. And we invite you to join our vaccine focused webinars.

    May 17, 2019
    Mitchell Warren
  • This HVAD, AVAC has an updated toolkit of resources for translating HIV vaccine research with a renewed sense of urgency, and two dedicated hashtags to rally the call on social media: #HIVvaccineAware and #HVAD2019. We hope you’ll join the conversation!

    May 15, 2019
    Antibody Related Research, HIV Vaccine
    AVAC
  • In early May, AVAC joined Zambian civil society organizations for a kick-off meeting to plan the country’s Key Population Investment Fund activities. The lessons learned there are highly relevant to civil society in every country where KPIF will be introduced. This is time sensitive and urgent for all of us who want to see this investment have a meaningful impact.

    May 14, 2019
    General
    AVAC
  • Gilead’s donation is an acknowledgment that there is a huge issue with PrEP access in America, as in many parts of the world. We welcome this indication that the company grasps the gravity of the situation. However, we urgently need a lower price for all. It’s disappointing that even this small step has taken so long.

    May 14, 2019
    Mitchell Warren

Pages